Short- and long-acting synthetic pentasaccharides as antithrombotic agents

Expert Opinion on Investigational Drugs

Volumn 14, Issue 7, 2005, Pages 847-858

  Walenga, Jeanine M ^a   Jeske, Walter P ^b   Fareed, Jawed ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Arixtra ; Fondaparinux; Heparin; Idraparinux; Pentasaccharide; Synthetic

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HEPARINOID; HEXADIMETHRINE BROMIDE; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BINDING SITE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG OVERDOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; EPIDURAL HEMATOMA; GROWTH INHIBITION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HIP SURGERY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; LUNG EMBOLISM; METHODOLOGY; NONHUMAN; PARALYSIS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE CARE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; SPINAL CORD HEMORRHAGE; ST SEGMENT ELEVATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; THROMBOGENESIS; TOTAL HIP PROSTHESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTITHROMBIN III; DELAYED-ACTION PREPARATIONS; FIBRINOLYTIC AGENTS; HUMANS; POLYSACCHARIDES; THROMBOEMBOLISM;

EID: 22844436957     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.7.847     Document Type: Review

References (86)

1. PETITOU M, DUCHAUSSOY P, LEDERMAN I et al.: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-[i O-sulfo-α- D-glucopyranosyl)-(1-4)-O-(β-D-glucopyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-[i O-sulfo-α-D-glucopyranosyl)-(1-4)-[i O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucapyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohyd. Res. (1986) 147(2):221-236.
2. PETITOU M, DUCHAUSSOY P, LEDERMAN I et al.: Synthesis of heparin fragments: a methyl α-pentaoside with high affinity for antithrombin III. Carbohyd. Res. (1987) 167:67-75.
3. 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem. Biophys. Res. Commun. (1985) 128(1):134-140.
4. WALENGA JM, JESKE WP, BARA L, SAMAMA MM, FAREED J: Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb. Res. (1997) 86(1):1-36.
5. HERBERT JM, PETITOU M, LORMEAU JC: SR-90107A/ORG31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc. Drug Revs. (1997) 15:1-26.
6. LORMEAU JC, HERAULT JP: The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-Mediated neutralization of factor Xa. Thromb. Haemost. (1995) 74(6):1474-1477.
7. WALENGA JM, BARA L, PETITOU M et al.: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb. Res. (1988) 51(1):23-33.
8. BEGUIN S, CHOAY J, HEMKER HC: The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost. (1989) 61(3):397-401.
9. ZITOUN D, BARA L, BLOCH MF, SAMAMA MM: Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb. Res. (1994) 75(5):577-580.
10. KAISER B, HOPPENSTEADT DA, JESKE WP, WUN TC, FAREED J: Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro - modulatory action of glycosaminoglycans. Thromb. Res. (1994) 75(6):609-616.
11. WALENGA JM, FLORIAN M, HOPPENSTEADT DA et al.: Heparin, LMW hepatitis and HCII binding oligosaccharides, but not pentasaccharide, regulate TAFI. Thromb. Haemost. (2001) July (Suppl.):2011.
12. GEROTZIAFAS GT, BARA L, BLOCH MF, MAKRIS PE, SAMAMA MM: Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole blood. Thromb. Res. (1996) 81(4):491-496.
13. LORMEAU JC, HERAULT JP, HERBERT JM: Antithrombin mediated inhibition of factor VIIa-tissue Factor complex by a synthetic pentasaccharide representing the heparin binding site to AT. Thromb. Haemost. (1996) 76(1):5-8.
14. WIEBE E, O'BRIEN L, STAFFORD A, FREDENBURGH J, WEITZ J: Heparin catalysis of factor IXa inhibition by antithrombin: Pentasaccharide-induced conformational change in antithrombin predominates over the template effect. Thromb. Haemost. (2001) (Suppl.):P2101.
15. WALENGA JM, HOPPENSTEADT DA, MAYUGA M, SAMAMA MM, FAREED J: Functionality of pentasaccharide depends on endogenous antithrombin levels. Blood (2000) 96(11):817a.
16. WALENGA JM: Factor Xa inhibition in mediating antithrombotic actions: application of a synthetic heparin pentasaccharide. In: Paris: Universite Pierre et Marie Curie, Paris VI (1987).
17. BERNAT A, HOFFMANN P, SAINTE-MARIE M, HERBERT JM: The synthetic pentasaccharide SR90107A/ORG31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits. Fibrinolysis (1996) 10(3):151-157.
18. KAISER B, FAREED J: Effect of unfractionated heparin and a heparin pentasaccharide on the thrombolytic process in an experimental model in rabbits. Fibrinolysis (1996) 10(Suppl. 3):127.
19. PISLARU SV, PISLARU C, ZHU X et al.: Comparison of a synthetic antithrombin III-binding pentasaccharide and a standard heparin as an adjunct to coronary thrombolysis. Thromb. Haemost. (1998) 79(6):1130-1135.
20. SAVI P, CHONG BH, GREINACHER A et al.: Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood (2005) 105:139-144.
21. WALENGA JM, KOZA MJ, LEWIS BE, PIFARRE R: Relative heparin-induced thrombocytopenic potential of low molecular weight hepatitis and new antithrombotic agents. Clin. Applied Thromb. Hemost. (1996) 2(Suppl 1):S21-S27.
22. ELALAMY I, LECRUBIER C, POTEVIN F et al.: Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb. Haemost. (1995) 74(5):1384-1385.
23. AHMAD S, JESKE WP, WALENGA JM et al.: Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin. Applied Thromb. Hemost. (1999) 5(4):259-266.
24. WALENGA JM, FAREED J, PETITOU M et al.: Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb. Res. (1986) 43(2):243-248.
25. WALENGA JM, PETITOU M, LORMEAU JC et al.: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. (1987) 46(2):187-198.
26. JESKE WP: Pharmacologic studies on synthetic analogues of heparin with selective affinity to endogenous serine protease inhibitors. Chicago: Loyola University, Chicago, USA (1996).
27. HOBBELEN PM, VAN DINTHER TG, VOGEL GM et al.: Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb. Haemost. (1990) 63(2):265-270.
28. VOGEL GMT, MEULEMAN DG, BOURGONDIEN FGM, HOBBELEN PMJ: Comparison of two experimental thrombosis models in rats, effects of four glycosaminoglycans. Thromb. Res. (1989) 54:399-410.
29. CADROY Y, HANSON SR, HARKER LA: Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb. Haemost. (1993) 70(4):631-635.
30. VOGEL GM, VAN AMSTERDAM RG, KOP WJ, MEULEMAN DG: Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb. Haemost. (1993) 69(1):29-34.
31. SCHLITT A, BUERKE M, HAUROEDER B et al.: Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb. Haemost. (2003) 90(2):245-251.
32. BONEU B, NECCIARI J, CARIOU R et al.: Pharmacokinetics and tolerance of the natural pentasaccharide (SR-90107/Org31540) with high affinity to antithrombin III in man. Thromb. Haemost. (1995) 74(6):1468-1473.
33. CREPON B, DONAT F, BARZU T, HERAULT JP: Pharmacokinetic parameters of AT binding pentasaccharides in three animal species: Predictive value for humans. Thromb. Haemost. (1993) 69(6):654.
34. VAN AMSTERDAM RG, VOGEL GM, VISSER A et al.: Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arteriosc. Thromb. Vasc. Biol. (1995) 15(4):495-503.
35. DONAT F, DURET JP, SANTONI A et al.: The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinetics (2002) 2:1-9.
36. FONDAPARINUX SODIUM: In: AHFS Drug Information 2005. American Society of Health-System Pharmacists, Inc., Bethesda (2005):1446-1448.
37. PAOLUCCI F, CLAVIES MC, DONAT F, NECCIARI J: Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clinical Pharmacokinetics (2002) 2:11-18.
38. GEERTS WH, PINEO GF, HEIT JA et al.: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(Suppl. 3):338S-400S.
39. TURPIE AGG, GALLUS AS, HOEK JA, THE PENTASACSHARIDE INVESTIGATORS: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Eng. J. Med. (2001) 344:619-625.
40. TURPIE AG, BAUER KA, ERIKSSON BI, LASSEN MR, PENTATHLON 2000 SSC: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. [erratum appears in Lancet (2002) 360(9339):1102]. Lancet (2002) 359(9319):1721-1726.
41. LASSEN MR, BAUER KA, ERIKSSON BI, TURPIE AG FOR THE EPHESUS SC: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery; a randomised double-blind comparison. Lancet (2002) 359:1715-1720.
42. ERIKSSON BI, BAUER KA, LASSEN MR, TURPIE AG, STEERING COMMITTEE OF THE PENTASACCHARIDE IN HIP-FRACTURE SURGERY: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Eng. J. Med. (2001) 345(18):1298-1304.
43. BAUER KA, ERIKSSON BI, LASSEN MR, TURPIE AG, STEERING COMMITTEE OF THE PENTASACCHARIDE IN MAJOR KNEE SURGERY: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Eng. J. Med. (2001) 345(18):1305-1310.
44. ERIKSSON BI, LASSEN MR, PENTASACCHARIDE IN HIP-FRACTURE SURGERY PLUS INVESTIGATORS: Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch. Int. Med. (2003) 163(11):1337-1342.
45. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR: Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy endpoints. Chest (2004) 126(2):501-508.
46. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR: Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra™) administration in the prevention of venous thromboembolism after major orthopedic surgery. Blood (2001) 98(11):1119.
47. THE REMBRANT INVESTIGATORS: Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR-90107A/ORG31540) with pure anti-factor Xa activity. Circulation (2000) 102:2726-2731.
48. COHEN AT, GALLUS AS, LASSEN MR: Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS). J. Thromb. Haemost. (2003) 1(Suppl.):P2046.
49. AGNELLI G, BERGQVIST D, COHEN AF: A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study. J. thromb. Haemost. (2003) 1(Suppl.):OC006.
50. BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Int. Med. (2004) 140(11):867-873.
51. BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Eng. J. Med. (2003) 349(18):1695-1702.
52. COUSSEMENT PK, BASSAND JP, COVENS C et al.: A synthetic factor Xa inhibitor (ORG31540/SR-90107A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur. Heart J. (2001) 22(18):1716-1724.
53. SIMOONS ML: Oral presentation on the PENTUA clinical trial. 74th Annual Scientific Sessions of the American Heart Association, CA, USA (2001).
54. VUILLEMENOT A, SCHIELE F, MENEVEAU N et al.: Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent - a pilot study in the setting of coronary angioplasty. Thromb. Haemost. (1999) 81:214-220.
55. SULLIVAN SD, DAVIDSON BL, KAHN SR et al.: A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics (2004) 22(9):605-620.
56. SPRUILL WJ, WADE WE, LESLIE RB: A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. American Journal of Therapeutics (2004) 11(1):3-8.
57. GORDOIS A, POSNETT J, BORRIS L et al.: The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost. (2003) 1(10):2167-2174.
58. PARODY R, OLIVER A, SOUTO JC, FONTCUBERTA J: Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated hepatitis. Haematologica (2003) 88(11):ECR 32.
59. D'AMICO EA, VILLACA PR, GUALANDRO SF, BASSITT RP, CHAMONE DA: Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J. Thromb. Haemost. (2003) 1(11):2452-2453.
60. BRADNER J, HALLISEY RK, KUTER DJ: Fondaparinux in the treatment of heparin-induced thrombocytopenia. Blood (2004) 104(11):(Abstract 1775).
61. FAAIJ RA, BURGGRAAF J, SCHOEMAKER RC et al.: The influence of renal function on the pharmacokinetics and pharmacodynamics of ORG31540/SR-90107A. Thromb. Haemost. (1997) June (Suppl.):379.
62. FAAIJ RA, BURGGRAAF J, SCHOEMAKER RC, VAN AMSTERDAM RG, COHEN AF: Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br. J. Clin. Pharmacol. (2002) 54(3):304-308.
63. FAAIJ RA, BURGGRAAF J, SCHOEMAKER RC, DE GREEF R, COHEN AF: The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin. Clin. Pharmacokinet. (2002) 2:27-29.
64. DONAT F, OLLIER C, SANTONI A, DUVAUCHELLE T: Safety and pharmacokinetics of co-administration of the first synthetic factor Xa inhibitor and aspirin in human volunteers. Blood (2000) 96(11):54a.
65. DAUD AN, AHSAN A, IQBAL O et al.: Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications. Clin. Applied Thromb. Hemost. (2001) 7(1):58-64.
66. IQBAL O, SHADID H, SILVER PJ et al.: Heparinase is capable of neutralizing the anticoagulant and hemorrhagic effects of a synthetic pentasaccharide. Blood (2000) 96(11):52a.
67. SHRIVER Z, SUNDARAM M, VENKATARAMAN G et al.: Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proceedings of the National Academy of Sciences (2000) 97:10365-10370.
68. BIJSTERVELD NR, MOONS AH, BOEKHOLDT SM et al.: Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation (2002) 106(20):2550-2554.
69. FAREED J, FU K, MA Q et al.: Bleeding effects of heparinomimetics can be antagonized by activated prothrombin complex concentrates an r-FVIIa in monotherapeutic and combination regimens. Thromb. Haemost. (2001) July (Suppl.):P2635.
70. KUBERAN B, LECH MZ, BEELER DL, WU ZL, ROSENBERG RD: Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat. Biotech. (2003) 21(11):1343-1346.
71. SHORT PL: Sugar chemistry finding markets. Chem. Eng. News (2004) 82(6):14-17.
72. HERAULT JP, BERNAT A, ROYE F et al.: Pharmacokinetics of new synthetic heparin mimetics. Thromb. Haemost. (2002) 87:985-989.
73. HERAULT JP, CAPPELLE M, BERNAT A et al.: Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo. J. Thromb. Haemost. (2003) 1(9):1959-1965.
74. BAL DIT SOLLIER C, KANG C, BERGE N et al.: Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis. J. Thromb. Haemost. (2004) 2(6):925-930.
75. HERBERT JM, HERAULT JP, BERNAT A et al.: SR-123781A, as synthetic heparin mimetic. Thromb. Haemost. (2001) 85:852-860.
76. HERAULT JP, BERNAT A, GAICH C, HERBERT JM: Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Thromb. Haemost. (2002) 87:238-244.
77. VOGEL GM, MEULEMAN DG, VAN DINTHER TG et al.: Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. J. Thromb. Haemost. (2003) 1(9):1945-1954.
78. GOUIN-THIBAULT I, DINGLER E, MARIS FA, SAMAMA MM: In vitro interaction of the pentasaccharide idraparinux (SanOrg 34006) with unfractionated heparin. J. Thromb. Haemost. (2003) 1(9):2054-2056.
79. HERBERT JM, HERAULT JP, BERNAT A et al.: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood (1998) 91(11):4197-4205.
80. FAAIJ RA, BURGGRAAF J, SCHOEMAKER RC, VAN AMSTERDAM RGM, COHEN AF: A Phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SanOrg 34006 in healthy male and female elderly volunteers. Thromb. Haemost. (1999) (Suppl.):(Abstract 15547).
81. THE PERSIST INVESTIGATORS: A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J. Thromb. Haemost. (2004) 2(1):47-53.
82. REITER M, BUCEK RA, KOCA N, HEGER J, MINAR E: Idraparinux and liver enzymes: Observations from the PERSIST trial. Blood Coag. Fibrinolysis (2003) 14(1):61-65.
83. ORGANON'S IDRAPURINUX: A novel once weekly anticoagulant enters Phase III trials. NV Organon Press release, June 11 (2003).
84. MA Q, FAREED J: Idraparinux sodium. IDrugs (2004) 7(11):1028-1034.
85. TURPIE AG, BAUER KA, ERIKSSON BI, LASSEN MR FOR THE SC: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch. Int. Med. (2002) 162(16):1833-1840.
86. WEITZ JI, HIRSH J, SAMAMA MM: New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126:265S-286S.